1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,430 | 1,530 | 29.05. | |
| 1,500 | 1,580 | 29.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides | 1.082 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potential... ► Artikel lesen | |
| 20.05. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.05. | NanoViricides Announces Closing of ~$2 Million Registered Direct Offering | 630 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 18.05. | Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides | 693 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 15.05. | NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering | 498 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 15.05. | NanoViricides GAAP EPS of -$0.09 | 2 | Seeking Alpha | ||
| 15.05. | NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II | 465 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending March... ► Artikel lesen | |
| 11.05. | Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides | 638 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the... ► Artikel lesen | |
| 06.05. | D.Boral Capital: NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference | 721 | Newsfile | Shelton, Connecticut--(Newsfile Corp. - May 6, 2026) - NanoViricides, Inc. (NYSE American: NNVC), today announced its participation in the D. Boral Capital Global Conference, taking place May 7... ► Artikel lesen | |
| 04.05. | NanoViricides: NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA | 518 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 21.04. | Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides | 603 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 07.04. | Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides | 814 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 01.04. | Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides | 1.314 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to... ► Artikel lesen | |
| 11.03. | NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete | 939 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot... ► Artikel lesen | |
| 17.02. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 12.02. | MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides | 863 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the... ► Artikel lesen | |
| 10.02. | Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides | 777 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the... ► Artikel lesen | |
| 02.02. | NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres | 636 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 20.01. | DealFlow Events: NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference | 1.097 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| 13.01. | NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 | 897 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 22,600 | +6,10 % | EQS-AFR: Formycon AG: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und Quartals-/Zwischenmitteilungen | EQS Vorabbekanntmachung Finanzberichte: Formycon AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Formycon AG: Vorabbekanntmachung über die Veröffentlichung... ► Artikel lesen | |
| SMOLTEK NANOTECH | 0,367 | -5,90 % | Communiqué from the 2026 Annual General Meeting of Smoltek Nanotech Holding AB (publ) | ||
| RIBER | 15,840 | -0,13 % | Riber: Margen steigen, KI-Boom treibt - Hidden Champion vor nächsten Kursschub? | Hightech "Made in France" mit Rückenwind durch KI und Photoniks: Riber verbessert trotz leicht rückläufigem Umsatz deutlich seine Profitabilität und könnte vor einem neuen Wachstumszyklus stehen. Riber... ► Artikel lesen | |
| ONTO INNOVATION | 219,10 | -1,48 % | Onto Innovation Forecasts 30% Revenue Growth for 2026: Can It Deliver? | ||
| KOPIN | 4,822 | -7,23 % | KOPIN CORP - 8-K, Current Report | ||
| OBDUCAT | 0,110 | -15,38 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen | |
| CANATU | 10,180 | -10,39 % | Canatu Oyj: Inside information: Canatu announces a leadership transition - Dr. Maximilian Slawinski appointed as CEO and successor to Juha Kokkonen | Canatu Plc Inside information 11 May 2026 at 09:00 a.m. EEST
Inside information: Canatu announces a leadership transition - Dr. Maximilian Slawinski appointed as CEO and successor to Juha Kokkonen
Canatu's... ► Artikel lesen | |
| VEECO INSTRUMENTS | 49,550 | -2,50 % | SVP At Veeco Instruments Sells $2.20M Of Stock | ||
| NVE | 84,50 | -2,87 % | Dividendenbekanntmachungen (18.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2A SPA IT0001233417 - 0,104 EUR AIR LIQUIDE SA FR0000120073 - 3,7 EUR ALCOA CORPORATION CDIS AU0000339426 0,1 USD 0,086 EUR ALLISON... ► Artikel lesen | |
| NANOFORM FINLAND | 1,008 | +2,13 % | Nanoform Finland Oyj: Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology | Nanoform Finland Plc | Company Release | May 19, 2026 at 08:10:00 EEST
Record first quarter revenue, income and gross margin. Revenue grew by 45%, gross margin reached 94% and operating costs fell by... ► Artikel lesen | |
| SOLESENCE | 1,255 | -4,92 % | Solésence, Inc.: Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results | Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty... ► Artikel lesen | |
| GAUZY | 0,690 | +9,44 % | Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Delayed Filing of Annual Report on Form 20-F | TEL AVIV, Israel, May 26, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (NASDAQ: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that on May 19, 2026... ► Artikel lesen | |
| GOMSPACE | 1,951 | -4,08 % | GomSpace Group AB: Annual general meeting held in GomSpace Group AB (publ) | Today, the annual general meeting of 2026 has been held in GomSpace Group AB (publ) (the "Company" or "GomSpace"). Below follows a summary of the decisions taken by the annual general meeting (all... ► Artikel lesen | |
| XTPL | 13,720 | +4,57 % | EQS-News: XTPL S.A.: In Q1 2026 XTPL secures funding for further growth and launches commercialization of its new ODRA business line | Issuer: XTPL S.A.
/ Key word(s): Quarter Results/Interim Report
In Q1 2026 XTPL secures funding for further growth and launches commercialization of its new ODRA business line... ► Artikel lesen | |
| ZENTEK | 0,486 | -6,54 % | Zentek Ltd.: Zentek Announces Closing of Fully Subscribed Brokered LIFE Offering for Gross Proceeds of C$18 Million | Guelph, Ontario--(Newsfile Corp. - May 27, 2026) - Zentek Ltd. (TSXV: ZEN) (NASDAQ: ZTEK) ("Zentek" or the "Company") is pleased to announce the closing of its previously announced "best efforts"... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Der aktuelle Kurs liegt bei 1,480 Euro und damit +3,50 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.